2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 668

Progression of Unilateral Grade 2 Sacroiliitis in a Psoriatic Arthritis Cohort
Abstract Number: 799

Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the Eustar Database
Abstract Number: 2695

Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry
Abstract Number: 1707

Prolactin and Dehydroepiandrosterone Sulfate in Women with Active Systemic Lupus Erythematosus of Recent Onset Versus Chronic Inactive Patients
Abstract Number: 2466

Prolonged Delay in Presentation to Rheumatologists for Hispanic Patients with Rheumatoid Arthritis Contributes to Later Diagnosis and Treatment
Abstract Number: 2617

Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Abstract Number: 745

Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: A Multi-Center Cohort Study from China
Abstract Number: 1684

Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality
Abstract Number: 2475

Promis Pain Interference 6b and Fatigue 7a Short Forms and Profile-29 in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Abstract Number: 2481

Proposal to Re-Evaluate the Definition of Low Disease Activity in Routine Assesment of Patient Index Data 3 (RAPID3) in Rheumatoid Arthritis Patients
Abstract Number: 2930

Prospective Comparison of Remission and Lupus Low Disease Activity State – Effect on Disease Outcomes in Systemic Lupus Erythematosus
Abstract Number: 1727

Prospective Confirmation of Potential Link between Proton Pump Inhibitor Exposure and Calcinosis in Systemic Sclerosis
Abstract Number: 2786

Prospective Multicenter Validation Study of the Lupus Low Disease Activity State – a Treatment Target for Systemic Lupus Erythematosus
Abstract Number: 1420

Prospective Validation of Cone Beam Computed Tomography for the Assessment of Disease Progression in Linear Scleroderma of the Face
Abstract Number: 2450

Prosthetic Joint Infection in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].